Students from over 120 countries choose to study at Aston University - a safe and friendly campus enjoyed by a global, multicultural community. Birmingham is one of the UK’s most diverse cities and home to an unrivalled cultural heritage, top sporting events, music, performing arts and outstanding world cuisine.

Aston University

New Row

Contact expert @[Full Name](fullname), @[Job Title](job_title) at @[Organization](organization) for media, speaking, professional opportunities and more.

@[Full Name](fullname) at @[Organization](organization) | Contact Form

Expert Inquiry

Open Sans

In vitro and in vivo osteogenic potential of niobium‐doped 45S5 bioactive glass: A comparative study

Origin of micro-scale heterogeneity in polymerisation of photo-activated resin composites

Photo-polymerisation variables influence the structure and subsequent thermal response of dental resin matrices

Evaluation of effectiveness of 45S5 bioglass doped with niobium for repairing critical‐sized bone defect in in vitro and in vivo models

Insight into the atomic scale structure of CaF2-CaO-SiO2 glasses using a combination of neutron diffraction, 29Si solid state NMR, high energy X-ray diffraction, FTIR, and XPS

Professor Richard Martin's research interests include bioactive glass, structural studies, neutron scattering, advanced imaging, and biomedical materials.

Advanced Imaging

Structural Studies

Bioactive Glass

Glass

Neutron Scattering

Aston Research Explorer Profile

ResearchGate Citations

Google Scholar Citations

Aston University develops E.coli-killing glass

Glass-coated catheters could wipe out infections and save NHS millions

Aston University develops novel bone cancer therapy which has 99% success rate

A cancer-killing bone replacement wonder-material

aston-university-collaboration-to-develop-injectable-paste-which-could-treat-bone-cancer

Reader, Electrical, Electronic & Power Eng, Aston Institute of Materials Research (AIMR)

A £110k grant from Orthopaedic Research UK is to help to conduct the work Study is a collaboration with The Royal Orthopaedic Hospital Researchers to use gallium-doped bioglass to produce a substance with anticancer and bone regenerative properties.   Professor Richard Martin  Aston University is collaborating in research to develop an injectable paste which could treat bone cancer.

The Royal Orthopaedic Hospital has secured a £110,000 grant from Orthopaedic Research UK to conduct the work. The project will see researchers at the hospital and the University use gallium-doped bioglass to produce a substance with anticancer and bone regenerative properties. If proved effective it could be used to treat patients with primary and metastatic cancer. 

Gallium is a metallic element that when combined with bioactive glass can kill cancerous cells that remain when a tumour is removed. It also accelerates the regeneration of the bone and prevents bacterial contamination. A recent study led by Aston University found that bioactive glasses doped with the metal have a 99 percent success rate of eliminating cancerous cells. 

Dr Lucas Souza, research lab manager at the hospital’s Dubrowsky Lab is leading the project. He said : “Advances in treatment of bone cancer have reached a plateau over the past 40 years, in part due to a lack of research studies into treatments and the complexity and challenges that come with treating bone tumours. Innovative and effective therapeutic approaches are needed, and this grant provides vital funds for us to continue our research into the use of gallium-doped bioglass in the treatment of bone cancer.” 

Professor Richard Martin who is based in Aston University’s College of Engineering and Physical Sciences added: “The injectable paste will function as a drug delivery system for localised delivery of anticancer gallium ions and bisphosphonates whilst regenerating bone. Our hypothesis is that this will promote rapid bone formation and will prevent cancer recurrence by killing residual cancer cells and regulating local osteoclastic activity.”

It is hoped the new approach will be particularly useful in reducing cancer recurrence and implant site infections. It is also thought that it will reduce implant failure rates in cases of bone tumours where large resections for complete tumour removal is either not possible, or not recommended. This could include incidents when growths are located too close to vital organs or when major surgery will inflict more harm than benefit. It could also be used in combination with minimally invasive treatments such as cryoablation or radiofrequency ablation to manage metastatic bone lesions.

Dr Souza added: “The proposed biomaterial has the potential to drastically improve treatment outcomes of bone tumour patients by reducing cancer recurrence, implant-site infection rates, and implant failure rates leading to reduced time in hospital beds, less use of antibiotics, and fewer revision surgeries. Taken together, these benefits could improve survival rates, functionality and quality of life of bone cancer patients.” 

Other members of the team include the hospital’s Professor Adrian Gardner, director of research and development and Mr Jonathan Stevenson, orthopaedic oncology and arthroplasty consultant, Dr Eirini Theodosiou from Aston University and Professor Joao Lopes from the Brazilian Aeronautics Institute of Technology.

ENDS

About the Royal Orthopaedic Hospital NHS Foundation Trust The Royal Orthopaedic Hospital NHS Foundation Trust is one of the largest specialist orthopaedic units in Europe, offering planned orthopaedic surgery to people locally, nationally, and internationally. 
The Trust is an accredited Veteran Aware organisation and a Disability Confident Leader.   Ranked 8th in the 2024 UK Inclusive Top 50 Employers list, the Royal Orthopaedic Hospital is the highest-ranking NHS organisation for its commitment to diversity and inclusion. 
The Royal Orthopaedic Hospital has a vibrant research portfolio of clinical trials, observational studies and laboratory studies exploring new treatment options, new approaches in rehabilitation and therapy, and new medical devices. This research is delivered by our researchers and clinicians spread across the Knowledge Hub, our home for  education and research, and the Dubrowsky Regenerative Medicine Laboratory, a state-of-the-art lab opened in 2019.

About Aston University For over a century, Aston University’s enduring purpose has been to make our world a better place through education, research and innovation, by enabling our students to succeed in work and life, and by supporting our communities to thrive economically, socially and culturally.
Aston University’s history has been intertwined with the history of Birmingham, a remarkable city that once was the heartland of the Industrial Revolution and the manufacturing powerhouse of the world.
Born out of the First Industrial Revolution, Aston University has a proud and distinct heritage dating back to our formation as the School of Metallurgy in 1875, the first UK College of Technology in 1951, gaining university status by Royal Charter in 1966, and becoming The Guardian University of the Year in 2020.
Building on our outstanding past, we are now defining our place and role in the Fourth Industrial Revolution (and beyond) within a rapidly changing world.
For media inquiries in relation to this release, contact Nicola Jones, Press & Communications Manager on 07941194168 or email: n.jones6@aston.ac.uk



Aston University collaboration to develop injectable paste which could treat bone cancer

aston-university-develops-novel-bone-cancer-therapy-which-has-99-success-rate

  Bioactive glasses, doped with gallium developed to create a potential treatment for bone cancer Lab tests have a 99 percent success rate of killing cancerous cells  Method could also regenerate diseased bones.  Bioactive glasses, a filling material which can bond to tissue and improve the strength of bones and teeth, has been combined with gallium to create a potential treatment for bone cancer.

Tests in labs have found that bioactive glasses doped with the metal have a 99 percent success rate of eliminating cancerous cells and can even regenerate diseased bones.

The research was conducted by a team of Aston University scientists led by Professor Richard Martin who is based in its College of Engineering and Physical Sciences.

In laboratory tests 99% of osteosarcoma (bone cancer) cells were killed off without destroying non-cancerous normal human bone cells. The researchers also incubated the bioactive glasses in a simulated body fluid and after seven days they detected the early stages of bone formation. 

Gallium is highly toxic, and the researchers found that the ‘greedy’ cancer cells soak it up and self-kill, which prevented the healthy cells from being affected. Their research paper Multifunctional Gallium doped bioactive glasses: a targeted delivery for antineoplastic agents and tissue repair against osteosarcoma has been published in the journal Biomedical Materials.

Osteosarcoma is the mostly commonly occurring primary bone cancer and despite the use of chemotherapy and surgery to remove tumours survival rates have not improved much since the 1970s. Survival rates are dramatically reduced for patients who have a recurrence and primary bone cancer patients are more susceptible to bone fractures. 

Despite extensive research on different types of bioactive glass or ceramics for bone tissue engineering, there is limited research on targeted and controlled release of anti-cancer agents to treat bone cancers.

Professor Martin said: “There is an urgent need for improved treatment options and our experiments show significant potential for use in bone cancer applications as part of a multimodal treatment.

“We believe that our findings could lead to a treatment that is more effective and localised, reducing side effects, and can even regenerate diseased bones.

“When we observed the glasses, we could see the formation of a layer of amorphous calcium phosphate/ hydroxy apatite layer on the surface of the bioactive glass particulates, which indicates bone growth.”
The glasses were created in the Aston University labs by rapidly cooling very high temperature molten liquids (1450o C) to form glass. The glasses were then ground and sieved into tiny particles which can then be used for treatment.  

In previous research the team achieved a 50 percent success rate but although impressive this was not enough to be a potential treatment. The team are now hoping to attract more research funding to conduct trials using gallium.

Dr Lucas Souza, research laboratory manager for the Dubrowsky Regenerative Medicine Laboratory at the Royal Orthopaedic Hospital, Birmingham worked on the research with Professor Martin. He added: “The safety and effectiveness of these biomaterials will need to be tested further, but the initial results are really promising.

 
“Treatments for a bone cancer diagnosis remain very limited and there’s still much we don’t understand. Research like this is vital to support in the development of new drugs and new methodologies for treatment options.”

 Notes to Editors

Multifunctional Gallium doped bioactive glasses: a targeted delivery for antineoplastic agents and tissue repair against osteosarcoma


Shirin B. Hanaei1, Raghavan C. Murugesan1, Lucas Souza1, Juan I.C. Miranda1, Lee Jeys2,3, Ivan B. Wall3, and Richard A. Martin1
1. College of Engineering and Physical Sciences. Aston University, Aston Triangle, Birmingham, B4 7ET, UK
2. Oncology Department, The Royal Orthopaedic Hospital, Birmingham, B31 2AP, UK
3. College of Health and Life Sciences. Aston University, Aston Triangle, Birmingham, B4 7ET, UK


DOI 10.1088/1748-605X/ad76f1

About Aston University
For over a century, Aston University’s enduring purpose has been to make our world a better place through education, research and innovation, by enabling our students to succeed in work and life, and by supporting our communities to thrive economically, socially and culturally.
Aston University’s history has been intertwined with the history of Birmingham, a remarkable city that once was the heartland of the Industrial Revolution and the manufacturing powerhouse of the world.
Born out of the First Industrial Revolution, Aston University has a proud and distinct heritage dating back to our formation as the School of Metallurgy in 1875, the first UK College of Technology in 1951, gaining university status by Royal Charter in 1966, and becoming The Guardian University of the Year in 2020.
Building on our outstanding past, we are now defining our place and role in the Fourth Industrial Revolution (and beyond) within a rapidly changing world.
For media inquiries in relation to this release, contact Nicola Jones, Press and Communications Manager, on (+44) 7825 342091 or email: n.jones6@aston.ac.uk 

aston-university-partners-with-business-to-develop-antimicrobial-surfaces-to-prevent-spread-of-infection

  A leading London based architectural metalwork company, specialising in the design, fabrication and installation of bespoke metal products has entered into a Knowledge Transfer Partnership (KTP) with Aston University, with the aim of developing antimicrobial coatings as a way to reduce infection in high risk environments. 

The Aston University research team will work with John Desmond Limited to develop high end metallic products that can be used where there is a high risk of the spread of bacteria. The antimicrobial coating will be developed for use in communal areas on products such as handrails, balustrades, push plates, door handles and faceplates, – all of which are common in high traffic areas such as hospitals, doctors surgeries, dental practices, schools and transportation hubs.

A Knowledge Transfer Partnership (KTP) is a three-way partnership between a business, an academic partner and a graduate, called a KTP Associate. The UK-wide programme helps businesses to improve their competitiveness and productivity through the better use of knowledge, technology and skills. Aston University is the leading KTP provider within the Midlands.

Microbiologists from Aston University’s College of Health and Life Sciences and materials scientists from its College of Engineering and Physical Science will establish the effectiveness of the antimicrobial coatings against a panel of bacteria under a range of conditions to further optimise the surface performance. 

The team will support John Desmond Ltd to establish an in-house microbiology laboratory to enable extensive testing of the developed coatings which will be carried out under lab conditions. Information from the lab tests will provide supporting evidence to prospective clients of the antimicrobial coating’s efficacy, expected lifespan and performance under varying conditions.

Ian Desmond, owner of John Desmond Ltd, said: 

“We are very excited to be working with Aston University on this ground-breaking project to develop industrial coatings capable of reducing the spread of infection within public spaces. 

“We are confident that with the expert knowledge and experience that the Aston University team brings to this collaboration, we will succeed in formulating a potent cost-effective means to protect all of us from the threat of micro-organisms, and their impact on the environment in which we live and work.”

The Aston University academic team consists of Dr Tony Worthington, associate professor in clinical microbiology and infectious disease; Professor Anthony Hilton, and executive dean of the College of Health and Life Sciences, and Dr Richard Martin from the Aston Institute of Materials Research in the College of Engineering and Physical Science. 

Professor Anthony Hilton said: “I’m delighted to be able to work on this exciting project with John Desmond Ltd, bringing together a multi-disciplinary team of scientists and engineers from across Aston University to work with an industry partner.  

“Knowledge exchange between academia and industry is a core element of Aston University’s strategy and it is exciting to be part of a team developing a product which has the potential to have real impact in preventing and controlling infection.”

Dr Richard Martin, Aston Institute of Materials Research, said: “Over the past year, we have all become aware of just how important it is to limit the spread of microorganisms. This project is an exciting opportunity to develop new antimicrobial coatings that will significantly reduce the transmission of microorganisms from touchpoint surfaces such as door handles and handrails."

The research team have found that claims for the effectiveness of the anti-microbial properties of products already on the market are not always backed with scientifically rigorous evidence. As a result of this, these products have not been able to penetrate markets such as healthcare, where generic claims are not sufficient for buyers to change suppliers.

This KTP will establish a body of testing and efficacy data which will support the application and use of antimicrobial coatings in a range of settings where control of bacteria on environmental surfaces is critical for infection prevention and control.

You can visit our website for more information about The College of Health and Life Sciences and The College of Engineering and Physical Science at Aston University.





Aston University partners with business to develop antimicrobial surfaces to prevent spread of infection

BBC Midlands Today covers a new discovery by Dr Richard Martin at Aston University's School of Engineering and Applied Science that cobalt-doped glass can kill deadly bacteria linked to hospital-associated infections. The glassmaking technique is similar to that used for stained glass in the Middle Ages. Used at surgical wound sites, the powdered form of the glass could prevent bacteria from taking hold and causing infection. It's thought the innovation could also help in the fight against drug-resistant germs like MRSA.

Aston University scientist develops bacteria-killing 'stained glass'

Select Inquiry Type